|
| Press Releases |
|
 |
|
| Tuesday, July 23, 2024 |
|
|
Avance Clinical Appoints Asia Regional Director as Part of Global Expansion Program |
| Avance Clinical, the award-winning CRO for biotechs, is proud to announce the appointment of Jessica Han as Director, Asian Operations based out of Avance Clinical's Seoul, Korea office. more info >> |
|
| Tuesday, June 4, 2024 |
|
|
New Research Launched at BIO24 Finds CROs with In-house Regulatory Affairs Can Deliver 30% Savings, Halve Timelines and Cut Risks for Biotechs |
| Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs, is sharing new data at BIO 2024 from Frost & Sullivan research showing biotechs save more than 30% in costs and halve start-up times with CROs that have in-house scientific and regulatory affairs. more info >> |
|
| Friday, May 31, 2024 |
|
|
Avance Clinical Expands Specialist CNS, Cardiometabolic, and Rare Diseases CRO Services in Europe with Julius Clinical |
| Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs has signed a Memorandum of Understanding (MOU) with Julius Clinical, a leading CNS, cardiometabolic, and rare diseases specialist CRO with extensive site relationships in the region. more info >> |
|
| Wednesday, May 8, 2024 |
|
|
Avance Clinical Expands Further into APAC with New Clinical Operations in South Korea |
| Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs, will attend BIO Korea (May 8-10, 2024) and formally open new clinical operations in Seoul, South Korea. more info >> |
|
| Friday, April 19, 2024 |
|
|
Avance Clinical Showcases Clinical Excellence at World Orphan Drug Conference in Boston, April 23-25 |
| Avance Clinical, the award-winning North American and Australian market-leading CRO for biotechs, will attend World Orphan Drug Conference in Boston (April 23-25, 2024) to share their rare diseases drug development expertise with biotechs (booth #730). more info >> |
|
| Thursday, March 28, 2024 |
|
|
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 Study |
| Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs, will attend World Vaccine Congress in Washington DC (April 1-4, 2024) and share the latest clinical trial client news including the Uvax Bio announcement. (Booth #267) more info >> |
|
| Wednesday, February 28, 2024 |
|
|
Avance Clinical CEO Talks with SCRIP about US Biotech Sector "Green Shoots" and a New CRO Report |
| Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs, has today spoken with SCRIP about their positive outlook for the US biotech sector following the J.P. Morgan Healthcare Conference and Biotech Showcase meetings. (read the full article here) more info >> |
|
| Friday, January 12, 2024 |
|
|
Latest Analysis Reveals 65% of US Biotechs Struggle to Identify Suitable CRO Partner |
| Avance Clinical, the leading Australian and North American CRO for biotechs announced today that new industry analysis shows 60-65% of US biotechs face challenges identifying the right sized CRO partner that can deliver at every phase of their drug development program. The report found this directly affected clinical programs and budgets. more info >> |
|
| Thursday, October 19, 2023 |
|
|
Avance Clinical Invited to Brief 45 Korean Biotechs on Their GlobalReady Drug Development Pathway from Korea and Australia to the US |
| more info >> |
|
| Tuesday, May 30, 2023 |
|
|
Avance Clinical at ASCO & BIO 2023: Early Phase Oncology Trials Increasingly Elaborate and Demand More Patients |
| Avance Clinical, the leading award-winning Australian and North American CRO that offers ClinicReady and GlobalReady for early phase biotech companies to speed up the path to regulatory approval, says early phase oncology studies are increasingly more complex and demand more patients. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Everest Medicines Announces 2025 Interim Results: 'Dual-Engine' Strategy Driving Strong Synergies Between Commercialization and R&D
Sept 8, 2025 23:12 HKT/SGT
|
|
|
Revenue up 23x! Sigenergy Achieves Profitability in Three Years 
Sept 8, 2025 20:39 HKT/SGT
|
|
|
Emerging designers take the spotlight at YDC 2025
Sept 8, 2025 20:03 HKT/SGT
|
|
|
Radisson Continues to Expand Scope of Gold Mineralization at O'Brien with Latest Drill Results
Sept 8, 2025 18:39 HKT/SGT
|
|
|
Toni Bou Wins 19th Consecutive FIM Trial World Championship Title
Sept 8, 2025 18:53 JST
|
|
|
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
Sept 8, 2025 17:49 JST
|
|
|
Honda to Commercialize UNI-ONE Hands-Free Personal Mobility Device
Sept 8, 2025 15:56 JST
|
|
|
European Dairy Exports from Ireland to Asia Top EUR440 Million in 2024 as Ireland Launches EUR3.2 Million EU Campaign to Strengthen Partnerships
Sept 8, 2025 14:49 HKT/SGT
|
|
|
Mitsubishi Power Signs Contract to Supply Two M701JAC Gas Turbines to O Mon 4 Power Plant
Sept 8, 2025 15:36 JST
|
|
|
Fujitsu develops generative AI reconstruction technology for optimized and energy-efficient AI models based on Takane LLM
Sept 8, 2025 14:28 JST
|
|
|
Yuexiu REIT Disposes of 50% Interest in Yuexiu Financial Tower in Guangzhou and Reorganises the Remaining 50%
Sept 8, 2025 08:02 HKT/SGT
|
|
|
Hong Kong Watch & Clock Fair, Salon de TIME end on a high note
Sept 7, 2025 13:13 HKT/SGT
|
|
|
10th anniversary CENTRESTAGE concludes successfully
Sept 6, 2025 21:36 JST
|
|
|
Mitsubishi Power Receives Contract for Large-Scale GTCC Project with 2,800 MW Total Output for Taiwan's Tung Hsiao Power Plant
Sept 5, 2025 21:47 JST
|
|
|
Hitachi announces historic $1 billion USD manufacturing investment to power America's energy future through production of critical grid infrastructure
Sept 5, 2025 21:00 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
